MDS: No survival benefit with hypomethylating agents bridging therapy before allo-HSCT

Key clinical point: Bridging therapy with hypomethylating agents (HMAs) did not provide long-term survival benefit in patients with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Major finding: Overall survival was not significantly different among patients who received HMAs vs. best supportive care before allo-HSCT (hazard ratio, 0.86; P = .32).

Study details: Findings are from a meta-analysis of 7 retrospective studies including 820 patients with MDS, of which 395 patients received HMAs before allo-HSCT and the remaining patients received best supportive care.

,

Disclosures: The study was funded by Youth Science Foundation of National Natural Science Foundation of China. The authors declared no potential conflicts of interest.

Source: Liu L et al. Clin Exp Med. 2021 Apr 17. doi: 10.1007/s10238-021-00712-0.